During the past decade, C.A.P. Mosen Cinto Verdaguer conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "C.A.P. Mosen Cinto Verdaguer" are "Hypertension" (2 trials). Many other conditions were trialed in "C.A.P. Mosen Cinto Verdaguer" in a lesser frequency.

Most popular intervention types in "C.A.P. Mosen Cinto Verdaguer" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Fixed dose combination telmisartan 80 mg + HCTZ 12.5 mg" (1 trials), "Fixed dose combination telmisartan 80 mg + HCTZ 25 mg" (1 trials) and "telmisartan 80 mg + hydrochlorothiazide 25 mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "C.A.P. Mosen Cinto Verdaguer" are 2 trials for "All" genders.

Currently, there are NaN active trials in "C.A.P. Mosen Cinto Verdaguer". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in C.A.P. Mosen Cinto Verdaguer, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in C.A.P. Mosen Cinto Verdaguer, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".